In an adult with type 2 diabetes, how many days should dapagliflozin be discontinued before cardiac surgery?

Dapagliflozin Should Be Discontinued At Least 3 Days Before Cardiac Surgery

For cardiac surgery specifically, discontinue dapagliflozin at least 3 days (≥72 hours) before the scheduled procedure to minimize the risk of perioperative euglycemic diabetic ketoacidosis while maintaining cardiorenal protection. 1, 2

Guideline-Based Recommendations

The most recent and authoritative guidelines are consistent and clear:

• 2024 AHA/ACC/ACS Perioperative Guideline explicitly states that canagliflozin, dapagliflozin, and empagliflozin should be stopped ≥3 days before scheduled surgery (Class 1 recommendation, Level C-LD evidence) 1

• 2025 ADA Standards of Care recommends SGLT2 inhibitors be discontinued 3-4 days before surgery 3

• FDA Drug Label for Dapagliflozin mandates withholding for at least 3 days prior to major surgery or procedures with prolonged fasting 2

Rationale: Balancing Ketoacidosis Risk Against Cardiorenal Benefits

The Primary Concern: Euglycemic Diabetic Ketoacidosis

The 3-day discontinuation window is designed to reduce perioperative metabolic acidosis risk. SGLT2 inhibitors increase ketone production by promoting glucosuria and shifting metabolism toward fat oxidation. When combined with surgical stress, fasting, and reduced insulin availability, this creates a perfect storm for euglycemic DKA—a potentially life-threatening condition that presents with:

• Normal or mildly elevated glucose (<200 mg/dL)
• High anion gap metabolic acidosis (pH <7.3)
• Elevated serum and urine ketones
• Nonspecific symptoms (nausea, vomiting, tachypnea) that mimic routine postoperative findings 4, 5

Evidence From Cardiac Surgery Populations

Research specific to cardiac surgery demonstrates the complexity:

• Case series show euglycemic DKA occurring even when SGLT2i were held 1-5 days preoperatively 4, 5, with one patient developing DKA at 7 days post-discontinuation, suggesting variable drug clearance 5

• However, a 2025 retrospective study of 540 cardiac surgery patients found zero cases of euglycemic DKA when dapagliflozin was stopped 5 days before surgery 6, supporting that adequate discontinuation time is protective

• Emerging data suggest potential harm from discontinuation: A 2026 analysis found that stopping SGLT2i was associated with increased 90-day cardiac complications (adjusted OR 1.58 per discontinued day), with only 1/451 patients developing euglycemic DKA 7

Practical Implementation Algorithm

For Elective Cardiac Surgery:

1. Stop dapagliflozin 3 days (72 hours minimum) before surgery 1, 2

   • If morning dosing: Last dose should be 3 mornings before surgery day
   • If evening dosing: Last dose should be 3 evenings before surgery day

2. Ensure adequate hydration and avoid prolonged fasting 8

   • Consider glucose-containing IV fluids if prolonged NPO status
   • Maintain euvolemia to reduce ketone generation

3. Monitor for ketoacidosis risk factors:

   • Type 1 diabetes or insulin-dependent type 2 diabetes
   • Reduced food/fluid intake
   • Concurrent illness or infection
   • Alcohol consumption 9

For Semi-Urgent or Emergency Cardiac Surgery:

When 3-day discontinuation is not feasible:

1. Document time since last SGLT2i dose (critical for risk stratification)

2. Implement enhanced metabolic monitoring:

   • Check serum and urine ketones preoperatively and within 24 hours postoperatively
   • Monitor anion gap and pH closely
   • Maintain blood glucose 100-180 mg/dL 3, 10

3. Maintain glucose-containing IV fluids to suppress ketogenesis

4. Have low threshold for ketone testing if patient develops nausea, vomiting, tachypnea, or unexplained metabolic acidosis 4, 5

Postoperative Resumption

Resume dapagliflozin only when the patient is:

• Clinically stable
• Eating and drinking normally
• Capillary ketones <0.6 mmol/L (if measured)
• Typically 24-48 hours after surgery for same-day discharge, or when meeting above criteria for inpatients 8, 2

Critical Pitfalls to Avoid

1. Do not assume normal glucose excludes DKA: Euglycemic DKA presents with glucose <200 mg/dL, making diagnosis challenging 4, 5

2. Do not dismiss nonspecific symptoms: Nausea, vomiting, and tachypnea are common postoperatively but may signal euglycemic DKA in SGLT2i users 4

3. Do not restart too early: Ensure adequate oral intake and metabolic stability before resuming 8, 2

4. Do not forget to document: Clear communication about SGLT2i use and discontinuation timing is essential across the perioperative team 11

Special Considerations for Heart Failure Patients

For patients taking dapagliflozin for heart failure (not just diabetes), the risk-benefit calculation is more nuanced. Recent evidence suggests discontinuation may increase risk of heart failure decompensation 7, 12. However, current guidelines still recommend 3-day discontinuation for all indications 1, prioritizing ketoacidosis prevention until prospective trials clarify optimal management.

The 3-day minimum provides adequate drug clearance (dapagliflozin half-life ~12.9 hours) while maintaining a pragmatic balance between metabolic safety and cardiorenal protection 1, 2.